Literature DB >> 3435118

Penetration of sulbactam and ampicillin into cerebrospinal fluid of infants and young children with meningitis.

G Foulds1, T J McBride, A K Knirsch, W J Rodriguez, W N Khan.   

Abstract

Infusions of 50 mg of sulbactam per kg per day and 400 mg of ampicillin per kg per day in divided doses to infants and children with bacterial meningitis produced levels in cerebrospinal fluid approximately one-third those in serum. Concentrations in cerebrospinal fluid of 5.5 micrograms of sulbactam per ml and 16.0 micrograms of ampicillin per ml declined within a few days of therapy to 1.9 microgram of sulbactam per ml and 5.2 micrograms of ampicillin per ml.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3435118      PMCID: PMC175024          DOI: 10.1128/AAC.31.11.1703

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

1.  Antimicrobial susceptibility of Haemophilus influenzae.

Authors:  C Thornsberry; L A Kirven
Journal:  Antimicrob Agents Chemother       Date:  1974-11       Impact factor: 5.191

2.  Ampicillin-resistant Haemophilus influenzae type B infection.

Authors:  M O Tomeh; S E Starr; J E McGowan; P M Terry; A J Nahmias
Journal:  JAMA       Date:  1974-07-15       Impact factor: 56.272

3.  Editorial: Should ampicillin be abandoned for treatment of Haemophilus influenzae disease?

Authors:  J D Nelson
Journal:  JAMA       Date:  1974-07-15       Impact factor: 56.272

4.  CP-45,899, a beta-lactamase inhibitor that extends the antibacterial spectrum of beta-lactams: initial bacteriological characterization.

Authors:  A R English; J A Retsema; A E Girard; J E Lynch; W E Barth
Journal:  Antimicrob Agents Chemother       Date:  1978-09       Impact factor: 5.191

5.  Comparative pharmacokinetics and tissue penetration of sulbactam and ampicillin after concurrent intravenous administration.

Authors:  R M Brown; R Wise; J M Andrews; J Hancox
Journal:  Antimicrob Agents Chemother       Date:  1982-04       Impact factor: 5.191

6.  Clavulanic acid and CP-45,899: a comparison of their in vitro activity in combination with penicillins.

Authors:  R Wise; J M Andrews; K A Bedford
Journal:  J Antimicrob Chemother       Date:  1980-03       Impact factor: 5.790

7.  Inhibition kinetics of three R-factor-mediated beta-lactamases by a new beta-lactam sulfone (CP 45899).

Authors:  R Labia; V Lelievre; J Peduzzi
Journal:  Biochim Biophys Acta       Date:  1980-02-14

8.  A sulfone beta-lactam compound which acts as a beta-lactamase inhibitor.

Authors:  N Aswapokee; H C Neu
Journal:  J Antibiot (Tokyo)       Date:  1978-12       Impact factor: 2.649

9.  CP-45,899 in combination with penicillin or ampicillin against penicillin-resistant Staphylococcus, Haemophilus influenzae, and Bacteroides.

Authors:  J A Retsema; A R English; A E Girard
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

10.  Pharmacokinetics of sulbactam in humans.

Authors:  G Foulds; J P Stankewich; D C Marshall; M M O'Brien; S L Hayes; D J Weidler; F G McMahon
Journal:  Antimicrob Agents Chemother       Date:  1983-05       Impact factor: 5.191

View more
  9 in total

1.  Evaluation of piperacillin-tazobactam in experimental meningitis caused by a beta-lactamase-producing strain of K1-positive Escherichia coli.

Authors:  W Kern; S L Kennedy; M Sachdeva; E R Sande; D Gunderson; M G Täuber
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

2.  Different ratios of the piperacillin-tazobactam combination for treatment of experimental meningitis due to Klebsiella pneumoniae producing the TEM-3 extended-spectrum beta-lactamase.

Authors:  G Leleu; M D Kitzis; J M Vallois; L Gutmann; J M Decazes
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

3.  Brain abscess caused by Brucella abortus and Staphylococcus aureus in a child.

Authors:  M Kalelioğlu; S Ceylan; I Köksal; K Kuzeyli; F Aktürk
Journal:  Infection       Date:  1990 Nov-Dec       Impact factor: 3.553

Review 4.  Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections.

Authors:  Roland Nau; Fritz Sörgel; Helmut Eiffert
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

Review 5.  Pharmacokinetics of antibacterial agents in the CSF of children and adolescents.

Authors:  Amanda K Sullins; Susan M Abdel-Rahman
Journal:  Paediatr Drugs       Date:  2013-04       Impact factor: 3.022

6.  Use of ampicillin-sulbactam for treatment of experimental meningitis caused by a beta-lactamase-producing strain of Escherichia coli K-1.

Authors:  L Guerra-Romero; S L Kennedy; M A Fournier; J H Tureen; M G Täuber
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

Review 7.  Ampicillin/sulbactam: current status in severe bacterial infections.

Authors:  Petros I Rafailidis; Eleni N Ioannidou; Matthew E Falagas
Journal:  Drugs       Date:  2007       Impact factor: 9.546

8.  Drug concentrations in the serum and cerebrospinal fluid of patients treated with cefoperazone/sulbactam after craniotomy.

Authors:  Qiang Wang; Yuanxing Wu; Biyao Chen; Jianxin Zhou
Journal:  BMC Anesthesiol       Date:  2015-03-13       Impact factor: 2.217

9.  Ampicillin/Sulbactam Treatment Modulates NMDA Receptor NR2B Subunit and Attenuates Neuroinflammation and Alcohol Intake in Male High Alcohol Drinking Rats.

Authors:  Fawaz Alasmari; Hasan Alhaddad; Woonyen Wong; Richard L Bell; Youssef Sari
Journal:  Biomolecules       Date:  2020-07-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.